Barely Significant
← all excerpts

Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region.

Clin Exp Allergy · 2025 · PMC12325141 · PMID 39988927

Europe PMCDOI
1
hedged sentence
0.0690
closest p · 1.4× alpha
0.0690
boldest claim

The sentences

showed a trendp = 0.0690so close (0.05 < p ≤ 0.1)
Post‐hoc analysis of the reduction in OCS dose from baseline to week 24 in the OCS maintenance group showed a trend towards greater reduction for dupilumab versus placebo (LS mean difference: 25.67 mg/day [95% CI: −2.00 to 53.34]; nominal p = 0.0690) (Table S5 ). 3.3.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.